ANIX — what changed in the latest 10-Q
A section-by-section comparison of ANIX's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-06-10 vs the prior 10-Q · 2026-03-09
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +9 | −2 | ~8 | 17 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 1 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-06-10
Research and development expenses decreased by approximately $64,000 to approximately $1,258,000 in the three months ended April 30, 2026, from approximately $1,322,000 in the three months ended April 30, 2025. The decrease in research and development expenses was primarily due to a decrease in empl…
General and administrative expenses decreased by approximately $292,000 to approximately $1,389,000 in the three months ended April 30, 2026, from approximately $1,681,000 in the three months ended April 30, 2025. The decrease in general and administrative expenses was primarily due to a decrease in…
Six months ended April 30, 2026 compared with six months ended April 30, 2025
We had no revenue during the six-month periods ended April 30, 2026 and 2025.
During the six months ended April 30, 2026, research and development expenses related to the development of our cancer vaccines and CAR-T therapeutics consisted of approximately $1,485,000 and $875,000, respectively. During the six months ended April 30, 2025 research and development expenses relate…
Text removed vs the prior filing · source: 10-Q · 2026-03-09
Research and development expenses decreased by approximately $450,000 to approximately $1,102,000 in the three months ended January 31, 2026, from approximately $1,552,000 in the three months ended January 31, 2025. The decrease in research and development expenses was primarily due to a decrease in…
General and administrative expenses decreased by approximately $220,000 to approximately $1,614,000 in the three months ended January 31, 2026, from approximately $1,834,000 in the three months ended January 31, 2025. The decrease in general and administrative expenses was primarily due to a decreas…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice